#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. Angiogenesis in Glioblastomas
1-1	0-2	6.	quantity	new	_	_
1-2	3-15	Angiogenesis	abstract[2]	new[2]	coref	2-14[9_2]
1-3	16-18	in	abstract[2]	new[2]	_	_
1-4	19-32	Glioblastomas	abstract[2]|abstract	new[2]|new	coref	2-3

#Text=Features of glioblastomas are a high propensity to invade the surrounding tissues and extensive angiogenesis .
2-1	33-41	Features	abstract[4]	new[4]	coref	2-5[6_4]
2-2	42-44	of	abstract[4]	new[4]	_	_
2-3	45-58	glioblastomas	abstract[4]|abstract	new[4]|giv	coref	8-11
2-4	59-62	are	_	_	_	_
2-5	63-64	a	abstract[6]	giv[6]	_	_
2-6	65-69	high	abstract[6]	giv[6]	_	_
2-7	70-80	propensity	abstract[6]	giv[6]	_	_
2-8	81-83	to	_	_	_	_
2-9	84-90	invade	_	_	_	_
2-10	91-94	the	object[7]|abstract[8]	new[7]|new[8]	ana|ana	3-1[0_8]|3-1[0_8]
2-11	95-106	surrounding	object[7]|abstract[8]	new[7]|new[8]	_	_
2-12	107-114	tissues	object[7]|abstract[8]	new[7]|new[8]	_	_
2-13	115-118	and	abstract[8]	new[8]	_	_
2-14	119-128	extensive	abstract[8]|abstract[9]	new[8]|giv[9]	coref	5-1[0_9]
2-15	129-141	angiogenesis	abstract[8]|abstract[9]	new[8]|giv[9]	_	_
2-16	142-143	.	_	_	_	_

#Text=They are characterized by a pathological vascular system with a dense network of winding vessels of different diameters , increased permeability , and with abnormally thickened basement membranes .
3-1	144-148	They	abstract	giv	_	_
3-2	149-152	are	_	_	_	_
3-3	153-166	characterized	_	_	_	_
3-4	167-169	by	_	_	_	_
3-5	170-171	a	abstract[11]	new[11]	_	_
3-6	172-184	pathological	abstract[11]	new[11]	_	_
3-7	185-193	vascular	abstract[11]	new[11]	_	_
3-8	194-200	system	abstract[11]	new[11]	_	_
3-9	201-205	with	_	_	_	_
3-10	206-207	a	abstract[12]	new[12]	coref	12-13[0_12]
3-11	208-213	dense	abstract[12]	new[12]	_	_
3-12	214-221	network	abstract[12]	new[12]	_	_
3-13	222-224	of	_	_	_	_
3-14	225-232	winding	_	_	_	_
3-15	233-240	vessels	object[13]	new[13]	coref	5-15[32_13]
3-16	241-243	of	object[13]	new[13]	_	_
3-17	244-253	different	object[13]|quantity[14]	new[13]|new[14]	_	_
3-18	254-263	diameters	object[13]|quantity[14]	new[13]|new[14]	_	_
3-19	264-265	,	object[13]	new[13]	_	_
3-20	266-275	increased	object[13]|abstract[15]	new[13]|new[15]	_	_
3-21	276-288	permeability	object[13]|abstract[15]	new[13]|new[15]	_	_
3-22	289-290	,	object[13]	new[13]	_	_
3-23	291-294	and	object[13]	new[13]	_	_
3-24	295-299	with	object[13]	new[13]	_	_
3-25	300-310	abnormally	object[13]|object[17]	new[13]|new[17]	_	_
3-26	311-320	thickened	object[13]|object[17]	new[13]|new[17]	_	_
3-27	321-329	basement	object[13]|place|object[17]	new[13]|new|new[17]	coref	7-26
3-28	330-339	membranes	object[13]|object[17]	new[13]|new[17]	_	_
3-29	340-341	.	_	_	_	_

#Text=These properties are often the cause of relapses and therapy failures because they hinder tumor access to cytotoxic chemotherapy .
4-1	342-347	These	abstract[18]	new[18]	coref	4-4[19_18]
4-2	348-358	properties	abstract[18]	new[18]	_	_
4-3	359-362	are	_	_	_	_
4-4	363-368	often	abstract[19]	giv[19]	ana	4-13[0_19]
4-5	369-372	the	abstract[19]	giv[19]	_	_
4-6	373-378	cause	abstract[19]	giv[19]	_	_
4-7	379-381	of	abstract[19]	giv[19]	_	_
4-8	382-390	relapses	abstract[19]|event	giv[19]|new	_	_
4-9	391-394	and	abstract[19]	giv[19]	_	_
4-10	395-402	therapy	abstract[19]|event|event[22]	giv[19]|new|new[22]	_	_
4-11	403-411	failures	abstract[19]|event[22]	giv[19]|new[22]	_	_
4-12	412-419	because	_	_	_	_
4-13	420-424	they	abstract	giv	_	_
4-14	425-431	hinder	_	_	_	_
4-15	432-437	tumor	abstract|abstract[25]	new|new[25]	coref|coref	5-7[30_0]|5-7[30_0]
4-16	438-444	access	abstract[25]	new[25]	_	_
4-17	445-447	to	abstract[25]	new[25]	_	_
4-18	448-457	cytotoxic	abstract[25]|place|substance[27]	new[25]|new|new[27]	_	_
4-19	458-470	chemotherapy	abstract[25]|substance[27]	new[25]|new[27]	_	_
4-20	471-472	.	_	_	_	_

#Text=Angiogenesis caused by the presence of a tumor is defined as the formation of new blood vessels based on existing ones , which can be visualized using ultra-high-field magnetic resonance angiography .
5-1	473-485	Angiogenesis	abstract	giv	coref	8-9[54_0]
5-2	486-492	caused	_	_	_	_
5-3	493-495	by	_	_	_	_
5-4	496-499	the	abstract[29]	new[29]	_	_
5-5	500-508	presence	abstract[29]	new[29]	_	_
5-6	509-511	of	abstract[29]	new[29]	_	_
5-7	512-513	a	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
5-8	514-519	tumor	abstract[29]|abstract[30]	new[29]|giv[30]	_	_
5-9	520-522	is	_	_	_	_
5-10	523-530	defined	_	_	_	_
5-11	531-533	as	_	_	_	_
5-12	534-537	the	_	_	_	_
5-13	538-547	formation	_	_	_	_
5-14	548-550	of	_	_	_	_
5-15	551-554	new	object[32]	giv[32]	coref	7-42[51_32]
5-16	555-560	blood	substance|object[32]	new|giv[32]	_	_
5-17	561-568	vessels	object[32]	giv[32]	_	_
5-18	569-574	based	_	_	_	_
5-19	575-577	on	_	_	_	_
5-20	578-586	existing	_	_	_	_
5-21	587-591	ones	object	new	_	_
5-22	592-593	,	_	_	_	_
5-23	594-599	which	_	_	_	_
5-24	600-603	can	_	_	_	_
5-25	604-606	be	_	_	_	_
5-26	607-617	visualized	_	_	_	_
5-27	618-623	using	_	_	_	_
5-28	624-640	ultra-high-field	object[35]	new[35]	_	_
5-29	641-649	magnetic	object[35]	new[35]	_	_
5-30	650-659	resonance	abstract|object[35]	new|new[35]	_	_
5-31	660-671	angiography	object[35]	new[35]	_	_
5-32	672-673	.	_	_	_	_

#Text=The mechanism of this process is very complex .
6-1	674-677	The	abstract[36]	new[36]	coref	15-9[103_36]
6-2	678-687	mechanism	abstract[36]	new[36]	_	_
6-3	688-690	of	abstract[36]	new[36]	_	_
6-4	691-695	this	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-5	696-703	process	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-6	704-706	is	_	_	_	_
6-7	707-711	very	_	_	_	_
6-8	712-719	complex	_	_	_	_
6-9	720-721	.	_	_	_	_

#Text=In GBM , the development of pathological vasculature is based on changes in adhesion molecules on the endothelial surface , the presence of an erratic basement membrane , a decrease in pericyte coverage , and a weaker binding of astrocytes to blood vessels .
7-1	722-724	In	_	_	_	_
7-2	725-728	GBM	place	new	coref	28-15
7-3	729-730	,	_	_	_	_
7-4	731-734	the	event[39]	new[39]	_	_
7-5	735-746	development	event[39]	new[39]	_	_
7-6	747-749	of	event[39]	new[39]	_	_
7-7	750-762	pathological	event[39]|object[40]	new[39]|new[40]	_	_
7-8	763-774	vasculature	event[39]|object[40]	new[39]|new[40]	_	_
7-9	775-777	is	_	_	_	_
7-10	778-783	based	_	_	_	_
7-11	784-786	on	_	_	_	_
7-12	787-794	changes	abstract[41]	new[41]	_	_
7-13	795-797	in	abstract[41]	new[41]	_	_
7-14	798-806	adhesion	abstract[41]|object[42]	new[41]|new[42]	_	_
7-15	807-816	molecules	abstract[41]|object[42]	new[41]|new[42]	_	_
7-16	817-819	on	abstract[41]|object[42]	new[41]|new[42]	_	_
7-17	820-823	the	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
7-18	824-835	endothelial	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
7-19	836-843	surface	abstract[41]|object[42]|place[43]	new[41]|new[42]|new[43]	_	_
7-20	844-845	,	_	_	_	_
7-21	846-849	the	abstract[44]	new[44]	_	_
7-22	850-858	presence	abstract[44]	new[44]	_	_
7-23	859-861	of	abstract[44]	new[44]	_	_
7-24	862-864	an	abstract[44]|object[46]	new[44]|new[46]	_	_
7-25	865-872	erratic	abstract[44]|object[46]	new[44]|new[46]	_	_
7-26	873-881	basement	abstract[44]|place|object[46]	new[44]|giv|new[46]	_	_
7-27	882-890	membrane	abstract[44]|object[46]	new[44]|new[46]	_	_
7-28	891-892	,	_	_	_	_
7-29	893-894	a	abstract[47]	new[47]	_	_
7-30	895-903	decrease	abstract[47]	new[47]	_	_
7-31	904-906	in	abstract[47]	new[47]	_	_
7-32	907-915	pericyte	abstract[47]|abstract[48]	new[47]|new[48]	_	_
7-33	916-924	coverage	abstract[47]|abstract[48]	new[47]|new[48]	_	_
7-34	925-926	,	_	_	_	_
7-35	927-930	and	_	_	_	_
7-36	931-932	a	object[49]	new[49]	_	_
7-37	933-939	weaker	object[49]	new[49]	_	_
7-38	940-947	binding	object[49]	new[49]	_	_
7-39	948-950	of	object[49]	new[49]	_	_
7-40	951-961	astrocytes	object[49]|abstract[50]	new[49]|new[50]	_	_
7-41	962-964	to	object[49]|abstract[50]	new[49]|new[50]	_	_
7-42	965-970	blood	object[49]|abstract[50]|object[51]	new[49]|new[50]|giv[51]	coref	8-32[63_51]
7-43	971-978	vessels	object[49]|abstract[50]|object[51]	new[49]|new[50]|giv[51]	_	_
7-44	979-980	.	_	_	_	_

#Text=A common element for the large invasiveness and angiogenesis of glioblastomas is the loss of tumor cell boundaries with the surrounding microenvironment consisting of brain tissue , subarachnoid space , and blood vessels .
8-1	981-982	A	abstract[52]	new[52]	coref	8-13[56_52]
8-2	983-989	common	abstract[52]	new[52]	_	_
8-3	990-997	element	abstract[52]	new[52]	_	_
8-4	998-1001	for	abstract[52]	new[52]	_	_
8-5	1002-1005	the	abstract[52]|abstract[53]	new[52]|new[53]	coref	26-14[0_53]
8-6	1006-1011	large	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-7	1012-1024	invasiveness	abstract[52]|abstract[53]	new[52]|new[53]	_	_
8-8	1025-1028	and	abstract[52]	new[52]	_	_
8-9	1029-1041	angiogenesis	abstract[52]|abstract[54]	new[52]|giv[54]	coref	9-1[0_54]
8-10	1042-1044	of	abstract[52]|abstract[54]	new[52]|giv[54]	_	_
8-11	1045-1058	glioblastomas	abstract[52]|abstract[54]|object	new[52]|giv[54]|giv	_	_
8-12	1059-1061	is	_	_	_	_
8-13	1062-1065	the	abstract[56]	giv[56]	_	_
8-14	1066-1070	loss	abstract[56]	giv[56]	_	_
8-15	1071-1073	of	abstract[56]	giv[56]	_	_
8-16	1074-1079	tumor	abstract[56]|place[58]	giv[56]|new[58]	_	_
8-17	1080-1084	cell	abstract[56]|place|place[58]	giv[56]|new|new[58]	coref	14-12
8-18	1085-1095	boundaries	abstract[56]|place[58]	giv[56]|new[58]	_	_
8-19	1096-1100	with	abstract[56]|place[58]	giv[56]|new[58]	_	_
8-20	1101-1104	the	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
8-21	1105-1116	surrounding	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
8-22	1117-1133	microenvironment	abstract[56]|place[58]|place[59]	giv[56]|new[58]|new[59]	_	_
8-23	1134-1144	consisting	_	_	_	_
8-24	1145-1147	of	_	_	_	_
8-25	1148-1153	brain	object|object[61]	new|new[61]	_	_
8-26	1154-1160	tissue	object[61]	new[61]	_	_
8-27	1161-1162	,	_	_	_	_
8-28	1163-1175	subarachnoid	place[62]	new[62]	_	_
8-29	1176-1181	space	place[62]	new[62]	_	_
8-30	1182-1183	,	_	_	_	_
8-31	1184-1187	and	_	_	_	_
8-32	1188-1193	blood	object[63]	giv[63]	_	_
8-33	1194-1201	vessels	object[63]	giv[63]	_	_
8-34	1202-1203	.	_	_	_	_

#Text=Angiogenesis occurs under the influence of various mechanisms , which we divide into hypoxia-dependent and hypoxia-independent .
9-1	1204-1216	Angiogenesis	substance	giv	coref	13-15
9-2	1217-1223	occurs	_	_	_	_
9-3	1224-1229	under	_	_	_	_
9-4	1230-1233	the	abstract[65]	new[65]	_	_
9-5	1234-1243	influence	abstract[65]	new[65]	_	_
9-6	1244-1246	of	abstract[65]	new[65]	_	_
9-7	1247-1254	various	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-8	1255-1265	mechanisms	abstract[65]|abstract[66]	new[65]|new[66]	_	_
9-9	1266-1267	,	_	_	_	_
9-10	1268-1273	which	_	_	_	_
9-11	1274-1276	we	person	acc	_	_
9-12	1277-1283	divide	_	_	_	_
9-13	1284-1288	into	_	_	_	_
9-14	1289-1306	hypoxia-dependent	abstract	new	_	_
9-15	1307-1310	and	_	_	_	_
9-16	1311-1330	hypoxia-independent	abstract	new	_	_
9-17	1331-1332	.	_	_	_	_

#Text=Hypoxia has been proven to inactivate prolyl hydroxylases .
10-1	1333-1340	Hypoxia	substance	new	ana	11-1
10-2	1341-1344	has	_	_	_	_
10-3	1345-1349	been	_	_	_	_
10-4	1350-1356	proven	_	_	_	_
10-5	1357-1359	to	_	_	_	_
10-6	1360-1370	inactivate	_	_	_	_
10-7	1371-1377	prolyl	abstract|substance[72]	new|new[72]	_	_
10-8	1378-1390	hydroxylases	substance[72]	new[72]	_	_
10-9	1391-1392	.	_	_	_	_

#Text=This increases the level of hypoxia-inducible factor-1α ( HIF-1α ) , causing the release of vascular endothelial growth factor ( VEGF ) by glioma cells affected by hypoxia .
11-1	1393-1397	This	substance	giv	coref	11-28
11-2	1398-1407	increases	_	_	_	_
11-3	1408-1411	the	abstract[74]	new[74]	_	_
11-4	1412-1417	level	abstract[74]	new[74]	_	_
11-5	1418-1420	of	abstract[74]	new[74]	_	_
11-6	1421-1438	hypoxia-inducible	abstract[74]|abstract[75]	new[74]|new[75]	appos	11-9[0_75]
11-7	1439-1448	factor-1α	abstract[74]|abstract[75]	new[74]|new[75]	_	_
11-8	1449-1450	(	_	_	_	_
11-9	1451-1457	HIF-1α	abstract	giv	_	_
11-10	1458-1459	)	_	_	_	_
11-11	1460-1461	,	_	_	_	_
11-12	1462-1469	causing	_	_	_	_
11-13	1470-1473	the	event[77]	new[77]	_	_
11-14	1474-1481	release	event[77]	new[77]	_	_
11-15	1482-1484	of	event[77]	new[77]	_	_
11-16	1485-1493	vascular	event[77]|abstract[80]	new[77]|new[80]	coref	13-10[93_80]
11-17	1494-1505	endothelial	event[77]|abstract|abstract[80]	new[77]|new|new[80]	_	_
11-18	1506-1512	growth	event[77]|abstract|abstract[80]	new[77]|new|new[80]	coref	12-12[90_0]
11-19	1513-1519	factor	event[77]|abstract[80]	new[77]|new[80]	_	_
11-20	1520-1521	(	_	_	_	_
11-21	1522-1526	VEGF	object	new	coref	12-4
11-22	1527-1528	)	_	_	_	_
11-23	1529-1531	by	_	_	_	_
11-24	1532-1538	glioma	abstract|object[83]	new|new[83]	coref|coref	20-9[134_0]|20-9[134_0]
11-25	1539-1544	cells	object[83]	new[83]	_	_
11-26	1545-1553	affected	_	_	_	_
11-27	1554-1556	by	_	_	_	_
11-28	1557-1564	hypoxia	event	giv	coref	13-6
11-29	1565-1566	.	_	_	_	_

#Text=The task of VEGF is to counteract oxygen deficiency by inducing vascular network growth .
12-1	1567-1570	The	abstract[85]	new[85]	_	_
12-2	1571-1575	task	abstract[85]	new[85]	_	_
12-3	1576-1578	of	abstract[85]	new[85]	_	_
12-4	1579-1583	VEGF	abstract[85]|substance	new[85]|giv	coref	15-3
12-5	1584-1586	is	_	_	_	_
12-6	1587-1589	to	_	_	_	_
12-7	1590-1600	counteract	_	_	_	_
12-8	1601-1607	oxygen	substance|abstract[88]	new|new[88]	_	_
12-9	1608-1618	deficiency	abstract[88]	new[88]	_	_
12-10	1619-1621	by	_	_	_	_
12-11	1622-1630	inducing	_	_	_	_
12-12	1631-1639	vascular	abstract[90]	giv[90]	coref	29-3[177_90]
12-13	1640-1647	network	abstract|abstract[90]	giv|giv[90]	_	_
12-14	1648-1654	growth	abstract[90]	giv[90]	_	_
12-15	1655-1656	.	_	_	_	_

#Text=In spite of this , hypoxia may not be the only trigger factor for angiogenesis .
13-1	1657-1659	In	_	_	_	_
13-2	1660-1665	spite	_	_	_	_
13-3	1666-1668	of	_	_	_	_
13-4	1669-1673	this	_	_	_	_
13-5	1674-1675	,	_	_	_	_
13-6	1676-1683	hypoxia	substance	giv	coref	14-12[99_0]
13-7	1684-1687	may	_	_	_	_
13-8	1688-1691	not	_	_	_	_
13-9	1692-1694	be	_	_	_	_
13-10	1695-1698	the	abstract[93]	giv[93]	_	_
13-11	1699-1703	only	abstract[93]	giv[93]	_	_
13-12	1704-1711	trigger	person|abstract[93]	new|giv[93]	_	_
13-13	1712-1718	factor	abstract[93]	giv[93]	_	_
13-14	1719-1722	for	abstract[93]	giv[93]	_	_
13-15	1723-1735	angiogenesis	abstract[93]|abstract	giv[93]|giv	ana	14-1
13-16	1736-1737	.	_	_	_	_

#Text=This applies particularly to the initial stages of carcinogenesis , when cell hypoxia is not yet severe .
14-1	1738-1742	This	abstract	giv	coref	17-15
14-2	1743-1750	applies	_	_	_	_
14-3	1751-1763	particularly	_	_	_	_
14-4	1764-1766	to	_	_	_	_
14-5	1767-1770	the	abstract[96]	new[96]	_	_
14-6	1771-1778	initial	abstract[96]	new[96]	_	_
14-7	1779-1785	stages	abstract[96]	new[96]	_	_
14-8	1786-1788	of	abstract[96]	new[96]	_	_
14-9	1789-1803	carcinogenesis	abstract[96]|abstract	new[96]|new	_	_
14-10	1804-1805	,	_	_	_	_
14-11	1806-1810	when	_	_	_	_
14-12	1811-1815	cell	place|event[99]	giv|giv[99]	coref|coref|coref|coref	15-13[0_99]|18-25|15-13[0_99]|18-25
14-13	1816-1823	hypoxia	event[99]	giv[99]	_	_
14-14	1824-1826	is	_	_	_	_
14-15	1827-1830	not	_	_	_	_
14-16	1831-1834	yet	_	_	_	_
14-17	1835-1841	severe	_	_	_	_
14-18	1842-1843	.	_	_	_	_

#Text=Regulation of VEGF secretion also takes place by a mechanism independent of hypoxia , involving dysregulated activation of mitogenic and survival pathways .
15-1	1844-1854	Regulation	event[100]	new[100]	_	_
15-2	1855-1857	of	event[100]	new[100]	_	_
15-3	1858-1862	VEGF	event[100]|abstract|abstract[102]	new[100]|giv|new[102]	coref|coref	17-13|17-13
15-4	1863-1872	secretion	event[100]|abstract[102]	new[100]|new[102]	_	_
15-5	1873-1877	also	_	_	_	_
15-6	1878-1883	takes	_	_	_	_
15-7	1884-1889	place	_	_	_	_
15-8	1890-1892	by	_	_	_	_
15-9	1893-1894	a	abstract[103]	giv[103]	_	_
15-10	1895-1904	mechanism	abstract[103]	giv[103]	_	_
15-11	1905-1916	independent	abstract[103]	giv[103]	_	_
15-12	1917-1919	of	_	_	_	_
15-13	1920-1927	hypoxia	event	giv	_	_
15-14	1928-1929	,	_	_	_	_
15-15	1930-1939	involving	_	_	_	_
15-16	1940-1952	dysregulated	abstract[105]	new[105]	ana	16-1[0_105]
15-17	1953-1963	activation	abstract[105]	new[105]	_	_
15-18	1964-1966	of	abstract[105]	new[105]	_	_
15-19	1967-1976	mitogenic	abstract[105]|place	new[105]|new	_	_
15-20	1977-1980	and	abstract[105]	new[105]	_	_
15-21	1981-1989	survival	abstract[105]|event|place[108]	new[105]|new|new[108]	coref|coref	27-13[0_108]|27-13[0_108]
15-22	1990-1998	pathways	abstract[105]|place[108]	new[105]|new[108]	_	_
15-23	1999-2000	.	_	_	_	_

#Text=This applies to phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase .
16-1	2001-2005	This	abstract	giv	_	_
16-2	2006-2013	applies	_	_	_	_
16-3	2014-2016	to	_	_	_	_
16-4	2017-2037	phosphatidylinositol	person	new	_	_
16-5	2038-2046	3-kinase	_	_	_	_
16-6	2047-2050	and	_	_	_	_
16-7	2051-2072	Ras/mitogen-activated	abstract[112]	new[112]	_	_
16-8	2073-2080	protein	substance|abstract[112]	new|new[112]	_	_
16-9	2081-2087	kinase	abstract[112]	new[112]	_	_
16-10	2088-2089	.	_	_	_	_

#Text=The PD-L1/PD-1 axis may also have roles in regulating the level of VEGF mediating angiogenesis .
17-1	2090-2093	The	abstract[114]	new[114]	coref	23-20[150_114]
17-2	2094-2104	PD-L1/PD-1	object|abstract[114]	new|new[114]	_	_
17-3	2105-2109	axis	abstract[114]	new[114]	_	_
17-4	2110-2113	may	_	_	_	_
17-5	2114-2118	also	_	_	_	_
17-6	2119-2123	have	_	_	_	_
17-7	2124-2129	roles	abstract	new	_	_
17-8	2130-2132	in	_	_	_	_
17-9	2133-2143	regulating	_	_	_	_
17-10	2144-2147	the	abstract[116]	new[116]	_	_
17-11	2148-2153	level	abstract[116]	new[116]	_	_
17-12	2154-2156	of	abstract[116]	new[116]	_	_
17-13	2157-2161	VEGF	abstract[116]|abstract	new[116]|giv	coref	18-16
17-14	2162-2171	mediating	_	_	_	_
17-15	2172-2184	angiogenesis	abstract	giv	coref	26-3[160_0]
17-16	2185-2186	.	_	_	_	_

#Text=In studies conducted by Shin et al. , a positive correlation between PDL1 levels and VEGF expression was shown in 197 patients with renal cell carcinoma .
18-1	2187-2189	In	_	_	_	_
18-2	2190-2197	studies	event	new	coref	22-1[141_0]
18-3	2198-2207	conducted	_	_	_	_
18-4	2208-2210	by	_	_	_	_
18-5	2211-2215	Shin	person	new	_	_
18-6	2216-2218	et	_	_	_	_
18-7	2219-2222	al.	_	_	_	_
18-8	2223-2224	,	_	_	_	_
18-9	2225-2226	a	abstract[121]	new[121]	_	_
18-10	2227-2235	positive	abstract[121]	new[121]	_	_
18-11	2236-2247	correlation	abstract[121]	new[121]	_	_
18-12	2248-2255	between	abstract[121]	new[121]	_	_
18-13	2256-2260	PDL1	abstract[121]|abstract|abstract[123]	new[121]|new|new[123]	coref|coref	21-6[138_123]|21-6[138_123]
18-14	2261-2267	levels	abstract[121]|abstract[123]	new[121]|new[123]	_	_
18-15	2268-2271	and	abstract[121]	new[121]	_	_
18-16	2272-2276	VEGF	abstract[121]|abstract|abstract[125]	new[121]|giv|new[125]	coref|coref|coref|coref	21-7[0_125]|21-12|21-7[0_125]|21-12
18-17	2277-2287	expression	abstract[121]|abstract[125]	new[121]|new[125]	_	_
18-18	2288-2291	was	_	_	_	_
18-19	2292-2297	shown	_	_	_	_
18-20	2298-2300	in	_	_	_	_
18-21	2301-2304	197	person[126]	new[126]	_	_
18-22	2305-2313	patients	person[126]	new[126]	_	_
18-23	2314-2318	with	person[126]	new[126]	_	_
18-24	2319-2324	renal	person[126]|abstract|object[129]	new[126]|new|new[129]	_	_
18-25	2325-2329	cell	person[126]|place|object[129]	new[126]|giv|new[129]	coref	26-11
18-26	2330-2339	carcinoma	person[126]|object[129]	new[126]|new[129]	_	_
18-27	2340-2341	.	_	_	_	_

#Text=Similar observations were noted by Song et al.
19-1	2342-2349	Similar	abstract[130]	new[130]	_	_
19-2	2350-2362	observations	abstract[130]	new[130]	_	_
19-3	2363-2367	were	_	_	_	_
19-4	2368-2373	noted	_	_	_	_
19-5	2374-2376	by	_	_	_	_
19-6	2377-2381	Song	person	new	_	_
19-7	2382-2384	et	_	_	_	_
19-8	2385-2388	al.	_	_	_	_

#Text=The study was conducted in 64 patients with primary glioma .
20-1	2389-2392	The	event[132]	new[132]	_	_
20-2	2393-2398	study	event[132]	new[132]	_	_
20-3	2399-2402	was	_	_	_	_
20-4	2403-2412	conducted	_	_	_	_
20-5	2413-2415	in	_	_	_	_
20-6	2416-2418	64	person[133]	new[133]	ana	21-3[0_133]
20-7	2419-2427	patients	person[133]	new[133]	_	_
20-8	2428-2432	with	person[133]	new[133]	_	_
20-9	2433-2440	primary	person[133]|abstract[134]	new[133]|giv[134]	_	_
20-10	2441-2447	glioma	person[133]|abstract[134]	new[133]|giv[134]	_	_
20-11	2448-2449	.	_	_	_	_

#Text=Also , they showed that PD-L1 expression levels correlated well with VEGF levels .
21-1	2450-2454	Also	_	_	_	_
21-2	2455-2456	,	_	_	_	_
21-3	2457-2461	they	person	giv	_	_
21-4	2462-2468	showed	_	_	_	_
21-5	2469-2473	that	_	_	_	_
21-6	2474-2479	PD-L1	abstract|abstract[138]	new|giv[138]	coref|coref	21-12[140_138]|21-12[140_138]
21-7	2480-2490	expression	abstract|abstract[138]	giv|giv[138]	coref	39-1[245_0]
21-8	2491-2497	levels	abstract[138]	giv[138]	_	_
21-9	2498-2508	correlated	_	_	_	_
21-10	2509-2513	well	_	_	_	_
21-11	2514-2518	with	_	_	_	_
21-12	2519-2523	VEGF	abstract|abstract[140]	giv|giv[140]	_	_
21-13	2524-2530	levels	abstract[140]	giv[140]	_	_
21-14	2531-2532	.	_	_	_	_

#Text=However , not all studies agreed on this point .
22-1	2533-2540	However	event[141]	giv[141]	_	_
22-2	2541-2542	,	event[141]	giv[141]	_	_
22-3	2543-2546	not	event[141]	giv[141]	_	_
22-4	2547-2550	all	event[141]	giv[141]	_	_
22-5	2551-2558	studies	event[141]	giv[141]	_	_
22-6	2559-2565	agreed	_	_	_	_
22-7	2566-2568	on	_	_	_	_
22-8	2569-2573	this	abstract[142]	new[142]	_	_
22-9	2574-2579	point	abstract[142]	new[142]	_	_
22-10	2580-2581	.	_	_	_	_

#Text=Research by Joseph et al. indicates the existence of a negative relationship between VEGF-related genes and the activity of the PD-L1/PD1 axis .
23-1	2582-2590	Research	organization[143]	new[143]	_	_
23-2	2591-2593	by	organization[143]	new[143]	_	_
23-3	2594-2600	Joseph	organization[143]|person	new[143]|new	_	_
23-4	2601-2603	et	organization[143]	new[143]	_	_
23-5	2604-2607	al.	organization[143]	new[143]	_	_
23-6	2608-2617	indicates	_	_	_	_
23-7	2618-2621	the	abstract[145]	new[145]	_	_
23-8	2622-2631	existence	abstract[145]	new[145]	_	_
23-9	2632-2634	of	abstract[145]	new[145]	_	_
23-10	2635-2636	a	abstract[145]|abstract[146]	new[145]|new[146]	coref	24-8[153_146]
23-11	2637-2645	negative	abstract[145]|abstract[146]	new[145]|new[146]	_	_
23-12	2646-2658	relationship	abstract[145]|abstract[146]	new[145]|new[146]	_	_
23-13	2659-2666	between	abstract[145]|abstract[146]	new[145]|new[146]	_	_
23-14	2667-2679	VEGF-related	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
23-15	2680-2685	genes	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
23-16	2686-2689	and	abstract[145]|abstract[146]	new[145]|new[146]	_	_
23-17	2690-2693	the	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
23-18	2694-2702	activity	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
23-19	2703-2705	of	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
23-20	2706-2709	the	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
23-21	2710-2719	PD-L1/PD1	abstract[145]|abstract[146]|abstract[148]|object|abstract[150]	new[145]|new[146]|new[148]|new|giv[150]	_	_
23-22	2720-2724	axis	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
23-23	2725-2726	.	_	_	_	_

#Text=A thorough understanding of the nature of this relationship requires further work .
24-1	2727-2728	A	abstract[151]	new[151]	_	_
24-2	2729-2737	thorough	abstract[151]	new[151]	_	_
24-3	2738-2751	understanding	abstract[151]	new[151]	_	_
24-4	2752-2754	of	abstract[151]	new[151]	_	_
24-5	2755-2758	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
24-6	2759-2765	nature	abstract[151]|abstract[152]	new[151]|new[152]	_	_
24-7	2766-2768	of	abstract[151]|abstract[152]	new[151]|new[152]	_	_
24-8	2769-2773	this	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
24-9	2774-2786	relationship	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
24-10	2787-2795	requires	_	_	_	_
24-11	2796-2803	further	abstract[154]	new[154]	ana	26-1[0_154]
24-12	2804-2808	work	abstract[154]	new[154]	_	_
24-13	2809-2810	.	_	_	_	_

#Text=EGF is another molecule with similar effects .
25-1	2811-2814	EGF	substance	new	coref	25-3[156_0]
25-2	2815-2817	is	_	_	_	_
25-3	2818-2825	another	substance[156]	giv[156]	coref	38-7[239_156]
25-4	2826-2834	molecule	substance[156]	giv[156]	_	_
25-5	2835-2839	with	substance[156]	giv[156]	_	_
25-6	2840-2847	similar	substance[156]|abstract[157]	giv[156]|new[157]	_	_
25-7	2848-2855	effects	substance[156]|abstract[157]	giv[156]|new[157]	_	_
25-8	2856-2857	.	_	_	_	_

#Text=It promotes tumor angiogenesis as well as an increase in cell motility and invasiveness .
26-1	2858-2860	It	abstract	giv	_	_
26-2	2861-2869	promotes	_	_	_	_
26-3	2870-2875	tumor	abstract|abstract[160]	new|giv[160]	coref|coref|coref|coref	28-15[175_160]|29-6|28-15[175_160]|29-6
26-4	2876-2888	angiogenesis	abstract[160]	giv[160]	_	_
26-5	2889-2891	as	_	_	_	_
26-6	2892-2896	well	_	_	_	_
26-7	2897-2899	as	_	_	_	_
26-8	2900-2902	an	abstract[161]	new[161]	ana	27-1[0_161]
26-9	2903-2911	increase	abstract[161]	new[161]	_	_
26-10	2912-2914	in	abstract[161]	new[161]	_	_
26-11	2915-2919	cell	abstract[161]|place|abstract[163]	new[161]|giv|new[163]	coref|coref	31-14|31-14
26-12	2920-2928	motility	abstract[161]|abstract[163]	new[161]|new[163]	_	_
26-13	2929-2932	and	abstract[161]	new[161]	_	_
26-14	2933-2945	invasiveness	abstract[161]|abstract	new[161]|giv	coref	37-14[236_0]
26-15	2946-2947	.	_	_	_	_

#Text=This is done by phosphorylating the EGFR receptor and activating further signaling pathways .
27-1	2948-2952	This	abstract	giv	ana	28-1
27-2	2953-2955	is	_	_	_	_
27-3	2956-2960	done	_	_	_	_
27-4	2961-2963	by	_	_	_	_
27-5	2964-2979	phosphorylating	_	_	_	_
27-6	2980-2983	the	substance[167]	new[167]	coref	36-25[228_167]
27-7	2984-2988	EGFR	abstract|substance[167]	new|new[167]	coref	28-6[170_0]
27-8	2989-2997	receptor	substance[167]	new[167]	_	_
27-9	2998-3001	and	_	_	_	_
27-10	3002-3012	activating	_	_	_	_
27-11	3013-3020	further	_	_	_	_
27-12	3021-3030	signaling	_	_	_	_
27-13	3031-3039	pathways	place	giv	_	_
27-14	3040-3041	.	_	_	_	_

#Text=It has been shown that both EGFR and its mutated form of EGFRvIII promote GBM angiogenesis .
28-1	3042-3044	It	abstract	giv	ana	28-9
28-2	3045-3048	has	_	_	_	_
28-3	3049-3053	been	_	_	_	_
28-4	3054-3059	shown	_	_	_	_
28-5	3060-3064	that	_	_	_	_
28-6	3065-3069	both	abstract[170]	giv[170]	coref	30-9[0_170]
28-7	3070-3074	EGFR	abstract[170]	giv[170]	_	_
28-8	3075-3078	and	_	_	_	_
28-9	3079-3082	its	abstract|abstract[172]	giv|new[172]	coref|coref	30-11[188_0]|30-11[188_0]
28-10	3083-3090	mutated	abstract[172]	new[172]	_	_
28-11	3091-3095	form	abstract[172]	new[172]	_	_
28-12	3096-3098	of	abstract[172]	new[172]	_	_
28-13	3099-3107	EGFRvIII	abstract[172]|abstract	new[172]|new	_	_
28-14	3108-3115	promote	_	_	_	_
28-15	3116-3119	GBM	abstract|abstract[175]	giv|giv[175]	coref|coref	31-26[0_175]|31-26[0_175]
28-16	3120-3132	angiogenesis	abstract[175]	giv[175]	_	_
28-17	3133-3134	.	_	_	_	_

#Text=To allow vasculature growth and tumor invasion , it is necessary to reduce the integrity of the tumor microenvironment .
29-1	3135-3137	To	_	_	_	_
29-2	3138-3143	allow	_	_	_	_
29-3	3144-3155	vasculature	organization|abstract[177]	new|giv[177]	coref|coref	41-17[0_177]|41-17[0_177]
29-4	3156-3162	growth	abstract[177]	giv[177]	_	_
29-5	3163-3166	and	_	_	_	_
29-6	3167-3172	tumor	abstract|event[179]	giv|new[179]	coref|coref|coref|coref	29-18|31-13[202_179]|29-18|31-13[202_179]
29-7	3173-3181	invasion	event[179]	new[179]	_	_
29-8	3182-3183	,	_	_	_	_
29-9	3184-3186	it	abstract	new	cata	29-9[0_181]
29-10	3187-3189	is	_	_	_	_
29-11	3190-3199	necessary	_	_	_	_
29-12	3200-3202	to	abstract[181]	new[181]	_	_
29-13	3203-3209	reduce	abstract[181]	new[181]	_	_
29-14	3210-3213	the	abstract[181]|abstract[182]	new[181]|new[182]	coref	31-7[199_182]
29-15	3214-3223	integrity	abstract[181]|abstract[182]	new[181]|new[182]	_	_
29-16	3224-3226	of	abstract[181]|abstract[182]	new[181]|new[182]	_	_
29-17	3227-3230	the	abstract[181]|abstract[182]|abstract[184]	new[181]|new[182]|new[184]	coref	31-7[0_184]
29-18	3231-3236	tumor	abstract[181]|abstract[182]|abstract|abstract[184]	new[181]|new[182]|giv|new[184]	coref	40-10
29-19	3237-3253	microenvironment	abstract[181]|abstract[182]|abstract[184]	new[181]|new[182]|new[184]	_	_
29-20	3254-3255	.	_	_	_	_

#Text=The pathophysiology of this process is based on EGFR inducing an increase in the activity of some proteases , thereby causing the breakdown of collagen , fibronectin , and other basement membrane structures .
30-1	3256-3259	The	abstract[185]	new[185]	_	_
30-2	3260-3275	pathophysiology	abstract[185]	new[185]	_	_
30-3	3276-3278	of	abstract[185]	new[185]	_	_
30-4	3279-3283	this	abstract[185]|event[186]	new[185]|new[186]	_	_
30-5	3284-3291	process	abstract[185]|event[186]	new[185]|new[186]	_	_
30-6	3292-3294	is	_	_	_	_
30-7	3295-3300	based	_	_	_	_
30-8	3301-3303	on	_	_	_	_
30-9	3304-3308	EGFR	abstract	giv	coref	32-8
30-10	3309-3317	inducing	_	_	_	_
30-11	3318-3320	an	abstract[188]	giv[188]	coref	31-23[205_188]
30-12	3321-3329	increase	abstract[188]	giv[188]	_	_
30-13	3330-3332	in	abstract[188]	giv[188]	_	_
30-14	3333-3336	the	abstract[188]|abstract[189]	giv[188]|new[189]	coref	32-3[208_189]
30-15	3337-3345	activity	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
30-16	3346-3348	of	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
30-17	3349-3353	some	abstract[188]|abstract[189]|object[190]	giv[188]|new[189]|new[190]	coref	32-1[207_190]
30-18	3354-3363	proteases	abstract[188]|abstract[189]|object[190]	giv[188]|new[189]|new[190]	_	_
30-19	3364-3365	,	_	_	_	_
30-20	3366-3373	thereby	_	_	_	_
30-21	3374-3381	causing	_	_	_	_
30-22	3382-3385	the	event[191]	new[191]	_	_
30-23	3386-3395	breakdown	event[191]	new[191]	_	_
30-24	3396-3398	of	event[191]	new[191]	_	_
30-25	3399-3407	collagen	event[191]|object	new[191]|new	_	_
30-26	3408-3409	,	event[191]	new[191]	_	_
30-27	3410-3421	fibronectin	event[191]|object	new[191]|new	_	_
30-28	3422-3423	,	event[191]	new[191]	_	_
30-29	3424-3427	and	event[191]	new[191]	_	_
30-30	3428-3433	other	event[191]|object[195]	new[191]|new[195]	_	_
30-31	3434-3442	basement	event[191]|object[195]	new[191]|new[195]	_	_
30-32	3443-3451	membrane	event[191]|object|object[195]	new[191]|new|new[195]	_	_
30-33	3452-3462	structures	event[191]|object[195]	new[191]|new[195]	_	_
30-34	3463-3464	.	_	_	_	_

#Text=The result is a loss of microenvironment integrity , an increase in tumor cell invasion into surrounding tissues and vessels , and an increase in angiogenesis .
31-1	3465-3468	The	abstract[196]	new[196]	coref	31-4[197_196]
31-2	3469-3475	result	abstract[196]	new[196]	_	_
31-3	3476-3478	is	_	_	_	_
31-4	3479-3480	a	abstract[197]	giv[197]	_	_
31-5	3481-3485	loss	abstract[197]	giv[197]	_	_
31-6	3486-3488	of	abstract[197]	giv[197]	_	_
31-7	3489-3505	microenvironment	abstract[197]|abstract|abstract[199]	giv[197]|giv|giv[199]	appos|coref|appos|coref	31-10[200_199]|49-15[321_0]|31-10[200_199]|49-15[321_0]
31-8	3506-3515	integrity	abstract[197]|abstract[199]	giv[197]|giv[199]	_	_
31-9	3516-3517	,	_	_	_	_
31-10	3518-3520	an	abstract[200]	giv[200]	coref	45-10[290_200]
31-11	3521-3529	increase	abstract[200]	giv[200]	_	_
31-12	3530-3532	in	abstract[200]	giv[200]	_	_
31-13	3533-3538	tumor	abstract[200]|event[202]	giv[200]|giv[202]	coref	47-7[307_202]
31-14	3539-3543	cell	abstract[200]|place|event[202]	giv[200]|giv|giv[202]	coref	44-18
31-15	3544-3552	invasion	abstract[200]|event[202]	giv[200]|giv[202]	_	_
31-16	3553-3557	into	abstract[200]|event[202]	giv[200]|giv[202]	_	_
31-17	3558-3569	surrounding	abstract[200]|event[202]|object[203]	giv[200]|giv[202]|new[203]	_	_
31-18	3570-3577	tissues	abstract[200]|event[202]|object[203]	giv[200]|giv[202]|new[203]	_	_
31-19	3578-3581	and	abstract[200]|event[202]	giv[200]|giv[202]	_	_
31-20	3582-3589	vessels	abstract[200]|event[202]|object	giv[200]|giv[202]|new	_	_
31-21	3590-3591	,	abstract[200]|event[202]	giv[200]|giv[202]	_	_
31-22	3592-3595	and	abstract[200]|event[202]	giv[200]|giv[202]	_	_
31-23	3596-3598	an	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	coref	39-6[246_205]
31-24	3599-3607	increase	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	_	_
31-25	3608-3610	in	abstract[200]|event[202]|abstract[205]	giv[200]|giv[202]|giv[205]	_	_
31-26	3611-3623	angiogenesis	abstract[200]|event[202]|abstract[205]|abstract	giv[200]|giv[202]|giv[205]|giv	_	_
31-27	3624-3625	.	_	_	_	_

#Text=The proteases whose activity is influenced by EGFR include , among others :
32-1	3626-3629	The	object[207]	giv[207]	coref	36-1[218_207]
32-2	3630-3639	proteases	object[207]	giv[207]	_	_
32-3	3640-3645	whose	abstract[208]	giv[208]	coref	40-4[250_208]
32-4	3646-3654	activity	abstract[208]	giv[208]	_	_
32-5	3655-3657	is	_	_	_	_
32-6	3658-3668	influenced	_	_	_	_
32-7	3669-3671	by	_	_	_	_
32-8	3672-3676	EGFR	abstract	giv	coref	41-14
32-9	3677-3684	include	_	_	_	_
32-10	3685-3686	,	_	_	_	_
32-11	3687-3692	among	_	_	_	_
32-12	3693-3699	others	_	_	_	_
32-13	3700-3701	:	_	_	_	_

#Text=Serine Proteases
33-1	3702-3708	Serine	substance[210]	new[210]	coref	36-1[0_210]
33-2	3709-3718	Proteases	substance[210]|abstract	new[210]|new	coref	35-1[216_0]

#Text=Matrix Metalloproteases ( MMPs )
34-1	3719-3725	Matrix	abstract|object[213]	new|new[213]	appos|coref|appos|coref	34-4[0_213]|46-10|34-4[0_213]|46-10
34-2	3726-3742	Metalloproteases	object[213]	new[213]	_	_
34-3	3743-3744	(	_	_	_	_
34-4	3745-3749	MMPs	object	giv	coref	43-16
34-5	3750-3751	)	_	_	_	_

#Text=Cysteine Proteases .
35-1	3752-3760	Cysteine	abstract|abstract[216]	new|giv[216]	coref|coref	48-6|48-6
35-2	3761-3770	Proteases	abstract[216]	giv[216]	_	_
35-3	3771-3772	.	_	_	_	_

#Text=Serine proteases are a large group of proteases which include tissue plasminogen activator ( tPA ) and urokinase plasminogen activator ( uPA ) with its receptor ( uPAR ) .
36-1	3773-3779	Serine	substance|abstract[218]	giv|giv[218]	coref|coref	36-4[219_218]|36-4[219_218]
36-2	3780-3789	proteases	abstract[218]	giv[218]	_	_
36-3	3790-3793	are	_	_	_	_
36-4	3794-3795	a	abstract[219]	giv[219]	ana	37-1[0_219]
36-5	3796-3801	large	abstract[219]	giv[219]	_	_
36-6	3802-3807	group	abstract[219]	giv[219]	_	_
36-7	3808-3810	of	abstract[219]	giv[219]	_	_
36-8	3811-3820	proteases	abstract[219]	giv[219]	_	_
36-9	3821-3826	which	_	_	_	_
36-10	3827-3834	include	_	_	_	_
36-11	3835-3841	tissue	object|organization[222]	new|new[222]	appos|appos	36-15[0_222]|36-15[0_222]
36-12	3842-3853	plasminogen	substance|organization[222]	new|new[222]	coref	36-19
36-13	3854-3863	activator	organization[222]	new[222]	_	_
36-14	3864-3865	(	_	_	_	_
36-15	3866-3869	tPA	organization	giv	_	_
36-16	3870-3871	)	_	_	_	_
36-17	3872-3875	and	_	_	_	_
36-18	3876-3885	urokinase	organization[225]	new[225]	appos	36-22[0_225]
36-19	3886-3897	plasminogen	substance|organization[225]	giv|new[225]	_	_
36-20	3898-3907	activator	organization[225]	new[225]	_	_
36-21	3908-3909	(	_	_	_	_
36-22	3910-3913	uPA	organization	giv	ana	36-25
36-23	3914-3915	)	_	_	_	_
36-24	3916-3920	with	_	_	_	_
36-25	3921-3924	its	organization|substance[228]	giv|giv[228]	coref|coref	41-3|41-3
36-26	3925-3933	receptor	substance[228]	giv[228]	_	_
36-27	3934-3935	(	_	_	_	_
36-28	3936-3940	uPAR	organization	new	coref	41-5
36-29	3941-3942	)	_	_	_	_
36-30	3943-3944	.	_	_	_	_

#Text=Their activation affects the degradation of the extracellular space by tumors , promoting their invasiveness .
37-1	3945-3950	Their	object|abstract[231]	giv|new[231]	ana|ana	37-14|37-14
37-2	3951-3961	activation	abstract[231]	new[231]	_	_
37-3	3962-3969	affects	_	_	_	_
37-4	3970-3973	the	abstract[232]	new[232]	ana	38-1[0_232]
37-5	3974-3985	degradation	abstract[232]	new[232]	_	_
37-6	3986-3988	of	abstract[232]	new[232]	_	_
37-7	3989-3992	the	abstract[232]|place[233]	new[232]|new[233]	_	_
37-8	3993-4006	extracellular	abstract[232]|place[233]	new[232]|new[233]	_	_
37-9	4007-4012	space	abstract[232]|place[233]	new[232]|new[233]	_	_
37-10	4013-4015	by	abstract[232]|place[233]	new[232]|new[233]	_	_
37-11	4016-4022	tumors	abstract[232]|place[233]|object	new[232]|new[233]|new	_	_
37-12	4023-4024	,	_	_	_	_
37-13	4025-4034	promoting	_	_	_	_
37-14	4035-4040	their	abstract|abstract[236]	giv|giv[236]	coref|coref|coref|coref	40-10[252_236]|43-11[274_0]|40-10[252_236]|43-11[274_0]
37-15	4041-4053	invasiveness	abstract[236]	giv[236]	_	_
37-16	4054-4055	.	_	_	_	_

#Text=It has been shown that , the PAI-1 molecule mediates the regulation of the uPA/uPAR pathway in astrocytoma cells .
38-1	4056-4058	It	abstract	giv	_	_
38-2	4059-4062	has	_	_	_	_
38-3	4063-4067	been	_	_	_	_
38-4	4068-4073	shown	_	_	_	_
38-5	4074-4078	that	_	_	_	_
38-6	4079-4080	,	_	_	_	_
38-7	4081-4084	the	substance[239]	giv[239]	ana	39-1[0_239]
38-8	4085-4090	PAI-1	substance|substance[239]	new|giv[239]	coref	42-8[264_0]
38-9	4091-4099	molecule	substance[239]	giv[239]	_	_
38-10	4100-4108	mediates	_	_	_	_
38-11	4109-4112	the	abstract[240]	new[240]	_	_
38-12	4113-4123	regulation	abstract[240]	new[240]	_	_
38-13	4124-4126	of	abstract[240]	new[240]	_	_
38-14	4127-4130	the	abstract[240]|place[242]	new[240]|new[242]	_	_
38-15	4131-4139	uPA/uPAR	abstract[240]|organization|place[242]	new[240]|new|new[242]	coref	40-5
38-16	4140-4147	pathway	abstract[240]|place[242]	new[240]|new[242]	_	_
38-17	4148-4150	in	abstract[240]|place[242]	new[240]|new[242]	_	_
38-18	4151-4162	astrocytoma	abstract[240]|place[242]|object[243]	new[240]|new[242]|new[243]	_	_
38-19	4163-4168	cells	abstract[240]|place[242]|object[243]	new[240]|new[242]|new[243]	_	_
38-20	4169-4170	.	_	_	_	_

#Text=Its expression is promoted by an increase in EGF and inflammatory cytokines .
39-1	4171-4174	Its	substance|abstract[245]	giv|giv[245]	coref|coref|coref|coref	39-9|41-10[256_245]|39-9|41-10[256_245]
39-2	4175-4185	expression	abstract[245]	giv[245]	_	_
39-3	4186-4188	is	_	_	_	_
39-4	4189-4197	promoted	_	_	_	_
39-5	4198-4200	by	_	_	_	_
39-6	4201-4203	an	abstract[246]	giv[246]	_	_
39-7	4204-4212	increase	abstract[246]	giv[246]	_	_
39-8	4213-4215	in	abstract[246]	giv[246]	_	_
39-9	4216-4219	EGF	abstract[246]|abstract	giv[246]|giv	coref	43-1
39-10	4220-4223	and	_	_	_	_
39-11	4224-4236	inflammatory	abstract[248]	new[248]	_	_
39-12	4237-4246	cytokines	abstract[248]	new[248]	_	_
39-13	4247-4248	.	_	_	_	_

#Text=This results in greater uPA/uPAR activity , thus increasing tumor invasiveness .
40-1	4249-4253	This	_	_	_	_
40-2	4254-4261	results	_	_	_	_
40-3	4262-4264	in	_	_	_	_
40-4	4265-4272	greater	abstract[250]	giv[250]	coref	42-11[266_250]
40-5	4273-4281	uPA/uPAR	organization|abstract[250]	giv|giv[250]	_	_
40-6	4282-4290	activity	abstract[250]	giv[250]	_	_
40-7	4291-4292	,	_	_	_	_
40-8	4293-4297	thus	_	_	_	_
40-9	4298-4308	increasing	_	_	_	_
40-10	4309-4314	tumor	abstract|abstract[252]	giv|giv[252]	coref|coref	42-16|42-16
40-11	4315-4327	invasiveness	abstract[252]	giv[252]	_	_
40-12	4328-4329	.	_	_	_	_

#Text=Upregulation of uPA and uPAR is also achieved through the expression of the EGFR ligand transforming growth factor ( TGFα ) .
41-1	4330-4342	Upregulation	abstract[253]	new[253]	_	_
41-2	4343-4345	of	abstract[253]	new[253]	_	_
41-3	4346-4349	uPA	abstract[253]|substance	new[253]|giv	coref	53-21
41-4	4350-4353	and	abstract[253]	new[253]	_	_
41-5	4354-4358	uPAR	abstract[253]|abstract	new[253]|giv	_	_
41-6	4359-4361	is	_	_	_	_
41-7	4362-4366	also	_	_	_	_
41-8	4367-4375	achieved	_	_	_	_
41-9	4376-4383	through	_	_	_	_
41-10	4384-4387	the	abstract[256]	giv[256]	coref	50-1[323_256]
41-11	4388-4398	expression	abstract[256]	giv[256]	_	_
41-12	4399-4401	of	abstract[256]	giv[256]	_	_
41-13	4402-4405	the	abstract[256]|abstract[258]	giv[256]|new[258]	_	_
41-14	4406-4410	EGFR	abstract[256]|abstract|abstract[258]	giv[256]|giv|new[258]	coref	42-11
41-15	4411-4417	ligand	abstract[256]|abstract[258]	giv[256]|new[258]	_	_
41-16	4418-4430	transforming	_	_	_	_
41-17	4431-4437	growth	abstract|abstract[260]	giv|new[260]	appos|appos	41-20[0_260]|41-20[0_260]
41-18	4438-4444	factor	abstract[260]	new[260]	_	_
41-19	4445-4446	(	_	_	_	_
41-20	4447-4451	TGFα	abstract	giv	_	_
41-21	4452-4453	)	_	_	_	_
41-22	4454-4455	.	_	_	_	_

#Text=Studies confirmed that in malignant gliomas , both PAI-1 and EGFR activity correlate with higher tumor malignancy and worse prognosis for patients .
42-1	4456-4463	Studies	abstract	new	_	_
42-2	4464-4473	confirmed	_	_	_	_
42-3	4474-4478	that	_	_	_	_
42-4	4479-4481	in	_	_	_	_
42-5	4482-4491	malignant	object[263]	new[263]	coref	46-39[303_263]
42-6	4492-4499	gliomas	object[263]	new[263]	_	_
42-7	4500-4501	,	_	_	_	_
42-8	4502-4506	both	substance[264]	giv[264]	_	_
42-9	4507-4512	PAI-1	substance[264]	giv[264]	_	_
42-10	4513-4516	and	_	_	_	_
42-11	4517-4521	EGFR	place|abstract[266]	giv|giv[266]	coref|coref	50-13|50-13
42-12	4522-4530	activity	abstract[266]	giv[266]	_	_
42-13	4531-4540	correlate	_	_	_	_
42-14	4541-4545	with	_	_	_	_
42-15	4546-4552	higher	abstract[268]	new[268]	coref	47-13[0_268]
42-16	4553-4558	tumor	event|abstract[268]	giv|new[268]	coref	47-7
42-17	4559-4569	malignancy	abstract[268]	new[268]	_	_
42-18	4570-4573	and	_	_	_	_
42-19	4574-4579	worse	abstract[269]	new[269]	_	_
42-20	4580-4589	prognosis	abstract[269]	new[269]	_	_
42-21	4590-4593	for	abstract[269]	new[269]	_	_
42-22	4594-4602	patients	abstract[269]|person	new[269]|new	ana	44-1
42-23	4603-4604	.	_	_	_	_

#Text=EGF also has a potential impact on another group of proteases , i. e. , MMPs .
43-1	4605-4608	EGF	abstract	giv	_	_
43-2	4609-4613	also	_	_	_	_
43-3	4614-4617	has	_	_	_	_
43-4	4618-4619	a	abstract[272]	new[272]	_	_
43-5	4620-4629	potential	abstract[272]	new[272]	_	_
43-6	4630-4636	impact	abstract[272]	new[272]	_	_
43-7	4637-4639	on	abstract[272]	new[272]	_	_
43-8	4640-4647	another	abstract[272]|abstract[273]	new[272]|new[273]	_	_
43-9	4648-4653	group	abstract[272]|abstract[273]	new[272]|new[273]	_	_
43-10	4654-4656	of	abstract[272]|abstract[273]	new[272]|new[273]	_	_
43-11	4657-4666	proteases	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	coref	48-4[0_274]
43-12	4667-4668	,	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
43-13	4669-4671	i.	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
43-14	4672-4674	e.	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
43-15	4675-4676	,	abstract[272]|abstract[273]|object[274]	new[272]|new[273]|giv[274]	_	_
43-16	4677-4681	MMPs	abstract[272]|abstract[273]|object[274]|object	new[272]|new[273]|giv[274]|giv	coref	53-23
43-17	4682-4683	.	_	_	_	_

#Text=They are a large group of enzymes whose effect is based on the regulation of metabolism and cell morphogenesis .
44-1	4684-4688	They	abstract	giv	coref	44-3[277_0]
44-2	4689-4692	are	_	_	_	_
44-3	4693-4694	a	abstract[277]	giv[277]	_	_
44-4	4695-4700	large	abstract[277]	giv[277]	_	_
44-5	4701-4706	group	abstract[277]	giv[277]	_	_
44-6	4707-4709	of	abstract[277]	giv[277]	_	_
44-7	4710-4717	enzymes	abstract[277]|substance	giv[277]|new	_	_
44-8	4718-4723	whose	abstract[279]	new[279]	_	_
44-9	4724-4730	effect	abstract[279]	new[279]	_	_
44-10	4731-4733	is	_	_	_	_
44-11	4734-4739	based	_	_	_	_
44-12	4740-4742	on	_	_	_	_
44-13	4743-4746	the	abstract[280]	new[280]	_	_
44-14	4747-4757	regulation	abstract[280]	new[280]	_	_
44-15	4758-4760	of	abstract[280]	new[280]	_	_
44-16	4761-4771	metabolism	abstract[280]|abstract|abstract[282]	new[280]|new|new[282]	ana|ana	45-3[0_282]|45-3[0_282]
44-17	4772-4775	and	abstract[280]|abstract[282]	new[280]|new[282]	_	_
44-18	4776-4780	cell	abstract[280]|abstract[282]|place|abstract[284]	new[280]|new[282]|giv|new[284]	coref|coref	45-10|45-10
44-19	4781-4794	morphogenesis	abstract[280]|abstract[282]|abstract[284]	new[280]|new[282]|new[284]	_	_
44-20	4795-4796	.	_	_	_	_

#Text=Disruption of their function also affects the loss of cell integrity .
45-1	4797-4807	Disruption	abstract[285]	new[285]	_	_
45-2	4808-4810	of	abstract[285]	new[285]	_	_
45-3	4811-4816	their	abstract[285]|abstract|abstract[287]	new[285]|giv|new[287]	_	_
45-4	4817-4825	function	abstract[285]|abstract[287]	new[285]|new[287]	_	_
45-5	4826-4830	also	_	_	_	_
45-6	4831-4838	affects	_	_	_	_
45-7	4839-4842	the	event[288]	new[288]	ana	46-1[0_288]
45-8	4843-4847	loss	event[288]	new[288]	_	_
45-9	4848-4850	of	event[288]	new[288]	_	_
45-10	4851-4855	cell	event[288]|place|abstract[290]	new[288]|giv|giv[290]	_	_
45-11	4856-4865	integrity	event[288]|abstract[290]	new[288]|giv[290]	_	_
45-12	4866-4867	.	_	_	_	_

#Text=It has been shown that the activity of certain matrix metalloproteases , such as MMP-2 ( gelatinase A ) , MMP-9 ( gelatinase B ) , MMP-14 ( matrix metalloproteinase 14 ) is related to the pathophysiology of high-grade gliomas .
46-1	4868-4870	It	event	giv	_	_
46-2	4871-4874	has	_	_	_	_
46-3	4875-4879	been	_	_	_	_
46-4	4880-4885	shown	_	_	_	_
46-5	4886-4890	that	_	_	_	_
46-6	4891-4894	the	abstract[292]	new[292]	_	_
46-7	4895-4903	activity	abstract[292]	new[292]	_	_
46-8	4904-4906	of	abstract[292]	new[292]	_	_
46-9	4907-4914	certain	abstract[292]|object[294]	new[292]|new[294]	_	_
46-10	4915-4921	matrix	abstract[292]|abstract|object[294]	new[292]|giv|new[294]	coref	46-29
46-11	4922-4938	metalloproteases	abstract[292]|object[294]	new[292]|new[294]	_	_
46-12	4939-4940	,	abstract[292]	new[292]	_	_
46-13	4941-4945	such	abstract[292]	new[292]	_	_
46-14	4946-4948	as	abstract[292]	new[292]	_	_
46-15	4949-4954	MMP-2	abstract[292]|abstract	new[292]|new	appos	46-17
46-16	4955-4956	(	_	_	_	_
46-17	4957-4967	gelatinase	abstract	giv	appos	46-23[298_0]
46-18	4968-4969	A	_	_	_	_
46-19	4970-4971	)	_	_	_	_
46-20	4972-4973	,	_	_	_	_
46-21	4974-4979	MMP-9	substance	new	_	_
46-22	4980-4981	(	_	_	_	_
46-23	4982-4992	gelatinase	abstract[298]	giv[298]	_	_
46-24	4993-4994	B	abstract[298]	giv[298]	_	_
46-25	4995-4996	)	_	_	_	_
46-26	4997-4998	,	_	_	_	_
46-27	4999-5005	MMP-14	object	new	appos	46-29[301_0]
46-28	5006-5007	(	_	_	_	_
46-29	5008-5014	matrix	abstract|object[301]	giv|giv[301]	_	_
46-30	5015-5032	metalloproteinase	object[301]	giv[301]	_	_
46-31	5033-5035	14	object[301]	giv[301]	_	_
46-32	5036-5037	)	_	_	_	_
46-33	5038-5040	is	_	_	_	_
46-34	5041-5048	related	_	_	_	_
46-35	5049-5051	to	_	_	_	_
46-36	5052-5055	the	abstract[302]	new[302]	ana	47-1[0_302]
46-37	5056-5071	pathophysiology	abstract[302]	new[302]	_	_
46-38	5072-5074	of	abstract[302]	new[302]	_	_
46-39	5075-5085	high-grade	abstract[302]|object[303]	new[302]|giv[303]	coref	51-11[0_303]
46-40	5086-5093	gliomas	abstract[302]|object[303]	new[302]|giv[303]	_	_
46-41	5094-5095	.	_	_	_	_

#Text=It correlates with the severity of tumor invasion and its degree of malignancy .
47-1	5096-5098	It	abstract	giv	ana	47-10
47-2	5099-5109	correlates	_	_	_	_
47-3	5110-5114	with	_	_	_	_
47-4	5115-5118	the	abstract[305]	new[305]	_	_
47-5	5119-5127	severity	abstract[305]	new[305]	_	_
47-6	5128-5130	of	abstract[305]	new[305]	_	_
47-7	5131-5136	tumor	abstract[305]|abstract|event[307]	new[305]|giv|giv[307]	coref|coref	49-16|49-16
47-8	5137-5145	invasion	abstract[305]|event[307]	new[305]|giv[307]	_	_
47-9	5146-5149	and	abstract[305]	new[305]	_	_
47-10	5150-5153	its	abstract[305]|abstract|abstract[309]	new[305]|giv|new[309]	_	_
47-11	5154-5160	degree	abstract[305]|abstract[309]	new[305]|new[309]	_	_
47-12	5161-5163	of	abstract[305]|abstract[309]	new[305]|new[309]	_	_
47-13	5164-5174	malignancy	abstract[305]|abstract[309]|abstract	new[305]|new[309]|giv	_	_
47-14	5175-5176	.	_	_	_	_

#Text=Another group of proteases are cysteine proteases , examples of which are cathepsins .
48-1	5177-5184	Another	abstract[311]	new[311]	coref	48-6[314_311]
48-2	5185-5190	group	abstract[311]	new[311]	_	_
48-3	5191-5193	of	abstract[311]	new[311]	_	_
48-4	5194-5203	proteases	abstract[311]|object	new[311]|giv	_	_
48-5	5204-5207	are	_	_	_	_
48-6	5208-5216	cysteine	abstract|abstract[314]	giv|giv[314]	_	_
48-7	5217-5226	proteases	abstract[314]	giv[314]	_	_
48-8	5227-5228	,	_	_	_	_
48-9	5229-5237	examples	object	new	coref	48-13
48-10	5238-5240	of	_	_	_	_
48-11	5241-5246	which	_	_	_	_
48-12	5247-5250	are	_	_	_	_
48-13	5251-5261	cathepsins	object	giv	_	_
48-14	5262-5263	.	_	_	_	_

#Text=These include , among others , cathepsin B , involved in the degradation of the tumor microenvironment .
49-1	5264-5269	These	_	_	_	_
49-2	5270-5277	include	_	_	_	_
49-3	5278-5279	,	_	_	_	_
49-4	5280-5285	among	_	_	_	_
49-5	5286-5292	others	_	_	_	_
49-6	5293-5294	,	_	_	_	_
49-7	5295-5304	cathepsin	person|substance[318]	new|new[318]	ana|coref|ana|coref	50-1[0_318]|52-4|50-1[0_318]|52-4
49-8	5305-5306	B	substance[318]	new[318]	_	_
49-9	5307-5308	,	_	_	_	_
49-10	5309-5317	involved	_	_	_	_
49-11	5318-5320	in	_	_	_	_
49-12	5321-5324	the	event[319]	new[319]	_	_
49-13	5325-5336	degradation	event[319]	new[319]	_	_
49-14	5337-5339	of	event[319]	new[319]	_	_
49-15	5340-5343	the	event[319]|object[321]	new[319]|giv[321]	_	_
49-16	5344-5349	tumor	event[319]|abstract|object[321]	new[319]|giv|giv[321]	coref	53-12[339_0]
49-17	5350-5366	microenvironment	event[319]|object[321]	new[319]|giv[321]	_	_
49-18	5367-5368	.	_	_	_	_

#Text=Its expression ( mRNA level ) has been shown to correlate with EGFR expression level .
50-1	5369-5372	Its	substance|abstract[323]	giv|giv[323]	appos|coref|appos|coref	50-4[325_323]|52-4[334_0]|50-4[325_323]|52-4[334_0]
50-2	5373-5383	expression	abstract[323]	giv[323]	_	_
50-3	5384-5385	(	_	_	_	_
50-4	5386-5390	mRNA	place|abstract[325]	new|giv[325]	coref|coref	50-13[327_325]|50-13[327_325]
50-5	5391-5396	level	abstract[325]	giv[325]	_	_
50-6	5397-5398	)	_	_	_	_
50-7	5399-5402	has	_	_	_	_
50-8	5403-5407	been	_	_	_	_
50-9	5408-5413	shown	_	_	_	_
50-10	5414-5416	to	_	_	_	_
50-11	5417-5426	correlate	_	_	_	_
50-12	5427-5431	with	_	_	_	_
50-13	5432-5436	EGFR	place|abstract[327]	giv|giv[327]	ana|ana	51-1[0_327]|51-1[0_327]
50-14	5437-5447	expression	abstract[327]	giv[327]	_	_
50-15	5448-5453	level	abstract[327]	giv[327]	_	_
50-16	5454-5455	.	_	_	_	_

#Text=It was also confirmed that its presence is increased in gliomas .
51-1	5456-5458	It	abstract	giv	ana	51-6
51-2	5459-5462	was	_	_	_	_
51-3	5463-5467	also	_	_	_	_
51-4	5468-5477	confirmed	_	_	_	_
51-5	5478-5482	that	_	_	_	_
51-6	5483-5486	its	abstract|abstract[330]	giv|new[330]	_	_
51-7	5487-5495	presence	abstract[330]	new[330]	_	_
51-8	5496-5498	is	_	_	_	_
51-9	5499-5508	increased	_	_	_	_
51-10	5509-5511	in	_	_	_	_
51-11	5512-5519	gliomas	object	giv	_	_
51-12	5520-5521	.	_	_	_	_

#Text=The action of cathepsin B may be bidirectional .
52-1	5522-5525	The	abstract[332]	new[332]	ana	53-1[0_332]
52-2	5526-5532	action	abstract[332]	new[332]	_	_
52-3	5533-5535	of	abstract[332]	new[332]	_	_
52-4	5536-5545	cathepsin	abstract[332]|person|object[334]	new[332]|giv|giv[334]	_	_
52-5	5546-5547	B	abstract[332]|object[334]	new[332]|giv[334]	_	_
52-6	5548-5551	may	_	_	_	_
52-7	5552-5554	be	_	_	_	_
52-8	5555-5568	bidirectional	_	_	_	_
52-9	5569-5570	.	_	_	_	_

#Text=It promotes the degradation of the integrity of the environment of the tumor directly or through intermediate mediators such as uPA , MMPs , or plasmin .
53-1	5571-5573	It	abstract	giv	_	_
53-2	5574-5582	promotes	_	_	_	_
53-3	5583-5586	the	abstract[336]	new[336]	_	_
53-4	5587-5598	degradation	abstract[336]	new[336]	_	_
53-5	5599-5601	of	abstract[336]	new[336]	_	_
53-6	5602-5605	the	abstract[336]|abstract[337]	new[336]|new[337]	_	_
53-7	5606-5615	integrity	abstract[336]|abstract[337]	new[336]|new[337]	_	_
53-8	5616-5618	of	abstract[336]|abstract[337]	new[336]|new[337]	_	_
53-9	5619-5622	the	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
53-10	5623-5634	environment	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
53-11	5635-5637	of	abstract[336]|abstract[337]|place[338]	new[336]|new[337]|new[338]	_	_
53-12	5638-5641	the	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
53-13	5642-5647	tumor	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
53-14	5648-5656	directly	abstract[336]|abstract[337]|place[338]|abstract[339]	new[336]|new[337]|new[338]|giv[339]	_	_
53-15	5657-5659	or	_	_	_	_
53-16	5660-5667	through	_	_	_	_
53-17	5668-5680	intermediate	abstract[340]	new[340]	_	_
53-18	5681-5690	mediators	abstract[340]	new[340]	_	_
53-19	5691-5695	such	abstract[340]	new[340]	_	_
53-20	5696-5698	as	abstract[340]	new[340]	_	_
53-21	5699-5702	uPA	abstract[340]|substance	new[340]|giv	_	_
53-22	5703-5704	,	abstract[340]	new[340]	_	_
53-23	5705-5709	MMPs	abstract[340]|object	new[340]|giv	_	_
53-24	5710-5711	,	abstract[340]	new[340]	_	_
53-25	5712-5714	or	abstract[340]	new[340]	_	_
53-26	5715-5722	plasmin	abstract[340]|object	new[340]|new	_	_
53-27	5723-5724	.	_	_	_	_
